FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023692142> ?p ?o ?g. }

• W2023692142 endingPage "355" @default.
• W2023692142 startingPage "350" @default.
• W2023692142 abstract "Background —Aspirin (acetylsalicylic acid, ASA) is widely used for secondary prevention of ischemic vascular events, although its protection only occurs in 25% of patients. We previously demonstrated that platelet reactivity is enhanced by a prothrombotic effect of erythrocytes in a thromboxane-independent manner. This diminishes the antithrombotic therapeutic potential of ASA. Recent data from our laboratory indicate that the prothrombotic effect of erythrocytes also contains an ASA-sensitive component. In accordance with this observation, intermittent treatment with high-dose ASA reduced the prothrombotic effects of erythrocytes ex vivo in healthy volunteers. In the present study, the effects of platelet-erythrocyte interactions were evaluated ex vivo in 82 patients with vascular disease: 62 patients with ischemic heart disease treated with 200 mg ASA/d and 20 patients with ischemic stroke treated with 300 mg ASA/d. Methods and Results —Platelet activation (release reaction) and platelet recruitment (fluid-phase proaggregatory activity of cell-free releasates from activated platelets) were assessed after collagen stimulation (1 μg/mL) of platelets, platelet-erythrocyte mixtures, or whole blood. Platelet thromboxane A 2 synthesis was inhibited by >94% by ASA administration in all patients. Importantly, platelet recruitment followed one of three distinct patterns. In group A (n=32; 39%), platelet recruitment was blocked by ASA both in the presence and absence of erythrocytes. In group B (n=37; 45%), recruitment was abolished when platelets were evaluated alone but continued in the presence of erythrocytes, indicating a suboptimal effect of ASA on erythrocytes of this patient group. In group C (n=13; 16%), detectable recruitment in stimulated platelets alone persisted and was markedly enhanced by the presence of erythrocytes. Conclusions —In two thirds of a group of patients with vascular disease, 200 to 300 mg ASA was insufficient to block platelet reactivity in the presence of erythrocytes despite abolishing thromboxane A 2 synthesis. Platelet activation in the presence of erythrocytes can induce the release reaction and generate biologically active products that recruit additional platelets into a developing thrombus. Insufficient blockade of this proaggregatory property of erythrocytes can lead to development of additional ischemic complications." @default.
• W2023692142 created "2016-06-24" @default.
• W2023692142 creator A5029943902 @default.
• W2023692142 creator A5053316364 @default.
• W2023692142 creator A5057720141 @default.
• W2023692142 creator A5063532478 @default.
• W2023692142 creator A5065051001 @default.
• W2023692142 creator A5081223035 @default.
• W2023692142 creator A5081668122 @default.
• W2023692142 creator A5088216839 @default.
• W2023692142 creator A5091685133 @default.
• W2023692142 date "1998-02-03" @default.
• W2023692142 modified "2023-09-25" @default.
• W2023692142 title "Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality" @default.
• W2023692142 cites W1235654702 @default.
• W2023692142 cites W142639968 @default.
• W2023692142 cites W1568317078 @default.
• W2023692142 cites W1966653330 @default.
• W2023692142 cites W1982346511 @default.
• W2023692142 cites W2026695328 @default.
• W2023692142 cites W2035619942 @default.
• W2023692142 cites W2059064084 @default.
• W2023692142 cites W2093366950 @default.
• W2023692142 cites W2100858861 @default.
• W2023692142 cites W2125389594 @default.
• W2023692142 cites W2149994976 @default.
• W2023692142 cites W2331216347 @default.
• W2023692142 cites W2405738162 @default.
• W2023692142 cites W2422287227 @default.
• W2023692142 cites W4239471829 @default.
• W2023692142 cites W4252241269 @default.
• W2023692142 cites W4321060250 @default.
• W2023692142 cites W76482949 @default.
• W2023692142 doi "https://doi.org/10.1161/01.cir.97.4.350" @default.
• W2023692142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9468208" @default.
• W2023692142 hasPublicationYear "1998" @default.
• W2023692142 type Work @default.
• W2023692142 sameAs 2023692142 @default.
• W2023692142 citedByCount "158" @default.
• W2023692142 countsByYear W20236921422012 @default.
• W2023692142 countsByYear W20236921422013 @default.
• W2023692142 countsByYear W20236921422014 @default.
• W2023692142 countsByYear W20236921422015 @default.
• W2023692142 countsByYear W20236921422016 @default.
• W2023692142 countsByYear W20236921422017 @default.
• W2023692142 countsByYear W20236921422018 @default.
• W2023692142 countsByYear W20236921422019 @default.
• W2023692142 countsByYear W20236921422021 @default.
• W2023692142 countsByYear W20236921422022 @default.
• W2023692142 crossrefType "journal-article" @default.
• W2023692142 hasAuthorship W2023692142A5029943902 @default.
• W2023692142 hasAuthorship W2023692142A5053316364 @default.
• W2023692142 hasAuthorship W2023692142A5057720141 @default.
• W2023692142 hasAuthorship W2023692142A5063532478 @default.
• W2023692142 hasAuthorship W2023692142A5065051001 @default.
• W2023692142 hasAuthorship W2023692142A5081223035 @default.
• W2023692142 hasAuthorship W2023692142A5081668122 @default.
• W2023692142 hasAuthorship W2023692142A5088216839 @default.
• W2023692142 hasAuthorship W2023692142A5091685133 @default.
• W2023692142 hasBestOaLocation W20236921421 @default.
• W2023692142 hasConcept C126322002 @default.
• W2023692142 hasConcept C150903083 @default.
• W2023692142 hasConcept C1621761 @default.
• W2023692142 hasConcept C203014093 @default.
• W2023692142 hasConcept C207001950 @default.
• W2023692142 hasConcept C26291073 @default.
• W2023692142 hasConcept C2776785769 @default.
• W2023692142 hasConcept C2777015399 @default.
• W2023692142 hasConcept C2777628954 @default.
• W2023692142 hasConcept C2781024287 @default.
• W2023692142 hasConcept C2781128415 @default.
• W2023692142 hasConcept C3018697912 @default.
• W2023692142 hasConcept C71924100 @default.
• W2023692142 hasConcept C86803240 @default.
• W2023692142 hasConcept C89560881 @default.
• W2023692142 hasConcept C98274493 @default.
• W2023692142 hasConceptScore W2023692142C126322002 @default.
• W2023692142 hasConceptScore W2023692142C150903083 @default.
• W2023692142 hasConceptScore W2023692142C1621761 @default.
• W2023692142 hasConceptScore W2023692142C203014093 @default.
• W2023692142 hasConceptScore W2023692142C207001950 @default.
• W2023692142 hasConceptScore W2023692142C26291073 @default.
• W2023692142 hasConceptScore W2023692142C2776785769 @default.
• W2023692142 hasConceptScore W2023692142C2777015399 @default.
• W2023692142 hasConceptScore W2023692142C2777628954 @default.
• W2023692142 hasConceptScore W2023692142C2781024287 @default.
• W2023692142 hasConceptScore W2023692142C2781128415 @default.
• W2023692142 hasConceptScore W2023692142C3018697912 @default.
• W2023692142 hasConceptScore W2023692142C71924100 @default.
• W2023692142 hasConceptScore W2023692142C86803240 @default.
• W2023692142 hasConceptScore W2023692142C89560881 @default.
• W2023692142 hasConceptScore W2023692142C98274493 @default.
• W2023692142 hasIssue "4" @default.
• W2023692142 hasLocation W20236921421 @default.
• W2023692142 hasLocation W20236921422 @default.
• W2023692142 hasOpenAccess W2023692142 @default.
• W2023692142 hasPrimaryLocation W20236921421 @default.
• W2023692142 hasRelatedWork W1987509459 @default.

• next